AZD6244 versus pemetrexed (Alimta®) in patients with non-small cell lung cancer, who have failed one or two prior chemotherapy regimen
Study identifier:D1532C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase II, open, randomised study to assess the efficacy and safety of AZD6244 versus pemetrexed (Alimta®) in patients with non-small cell lung cancer, who have failed one or two prior chemotherapy regimen
Medical condition
Non-small Cell Lung Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD6244, Pemetrexed
Sex
All
Actual Enrollment
88
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2006
Primary Completion Date: 01 Jul 2007
Study Completion Date: 01 Dec 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Pemetrexed | Drug: Pemetrexed oral Other Name: Alimta® |
| Experimental: 2 AZD6244 | Drug: AZD6244 oral vial Other Name: ARRY-142886 |
Contacts
Investigators
Principal Investigator
Emerging Oncology Medical Science Director
AstraZeneca
